CLIN CHEM LAB MED:LC-MS/MS检测血浆、微透析液和尿液中妥布霉素和林可霉素的方法的建立和验证

2020-03-17 MedSci原创 MedSci原创

本研究目的是开发和验证一种亲水性相互作用液相色谱-电喷雾电离-串联质谱(HILIC-ESI-MS/MS)方法,用于测定血浆、微透析液和尿液中妥布霉素(TMC)和林可霉素(LMC)的含量。

本研究目的是开发和验证一种亲水性相互作用液相色谱-电喷雾电离-串联质谱(HILIC-ESI-MS/MS)方法,用于测定血浆、微透析液和尿液中妥布霉素(TMC)和林可霉素(LMC)的含量。

采用蛋白沉淀法从血浆中提取TMC和LMC,微量透析液和尿样稀释后进行仪器分析。流动相A为2 mM醋酸铵在10%乙腈中加入0.2%甲酸(v/v),流动相B为2 mM醋酸铵在90%乙腈中加入0.2%甲酸(v/v)。流动相B的80%-10%的梯度分离是用一个连续的亲锌色谱柱来完成的。采用梯度洗脱法(流动相B的100%-40%),在配备有螯合型螯合保护柱的螯合型螯合柱上分离LMC。以万古霉素(VCM)为内标。在血浆0.1-20 mg/L、LMC 0.05-20 mg/L、微透析液0.1-20 mg/L和尿液1-100 mg/L的浓度范围内进行二次校正。

对于TMS和LMC,基质效应、精密度和准确性、特异性和稳定性的验证测试均在±15%的接受标准内。

本研究描述的方法符合验证接受标准,适用于在羊模型中进行的药代动力学初步研究。

原始出处:

Saurabh Pandey,Jayesh Dhanani,Development and validation of LC-MS/MS methods to measure tobramycin and lincomycin in plasma, microdialysis fluid and urine: application to a pilot pharmacokinetic research study

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2023849, encodeId=f95820238495d, content=<a href='/topic/show?id=a5a861e329f' target=_blank style='color:#2F92EE;'>#林可霉素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61732, encryptionId=a5a861e329f, topicName=林可霉素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Fri Apr 10 08:16:07 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449388, encodeId=a9401449388b6, content=<a href='/topic/show?id=b3e24e442bc' target=_blank style='color:#2F92EE;'>#尿液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47442, encryptionId=b3e24e442bc, topicName=尿液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66095470791, createdName=zhaohui6733, createdTime=Thu Mar 19 08:16:07 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610350, encodeId=7f2f1610350da, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 19 08:16:07 CST 2020, time=2020-03-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2023849, encodeId=f95820238495d, content=<a href='/topic/show?id=a5a861e329f' target=_blank style='color:#2F92EE;'>#林可霉素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61732, encryptionId=a5a861e329f, topicName=林可霉素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Fri Apr 10 08:16:07 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449388, encodeId=a9401449388b6, content=<a href='/topic/show?id=b3e24e442bc' target=_blank style='color:#2F92EE;'>#尿液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47442, encryptionId=b3e24e442bc, topicName=尿液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66095470791, createdName=zhaohui6733, createdTime=Thu Mar 19 08:16:07 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610350, encodeId=7f2f1610350da, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 19 08:16:07 CST 2020, time=2020-03-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2023849, encodeId=f95820238495d, content=<a href='/topic/show?id=a5a861e329f' target=_blank style='color:#2F92EE;'>#林可霉素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61732, encryptionId=a5a861e329f, topicName=林可霉素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=991e83, createdName=wincls, createdTime=Fri Apr 10 08:16:07 CST 2020, time=2020-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449388, encodeId=a9401449388b6, content=<a href='/topic/show?id=b3e24e442bc' target=_blank style='color:#2F92EE;'>#尿液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47442, encryptionId=b3e24e442bc, topicName=尿液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66095470791, createdName=zhaohui6733, createdTime=Thu Mar 19 08:16:07 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610350, encodeId=7f2f1610350da, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 19 08:16:07 CST 2020, time=2020-03-19, status=1, ipAttribution=)]